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OncologyImprovements in treatment and earlier diagnosis have both contributed to increased sur-
vival for many cancer patients. Unfortunately, many treatments carry a risk of late effects
including cardiovascular diseases (CVDs), possibly leading to significant morbidity and
mortality. In this paper we describe current knowledge of the cardiotoxicity arising from
cancer treatments, outline gaps in knowledge, and indicate directions for future research
and guideline development, as discussed during the 2014 Cancer Survivorship Summit
organised by the European Organisation for Research and Treatment of Cancer (EORTC).
Better knowledge is needed of the late effects of modern systemic treatments and of radio-
therapy to critical structures of the heart, including the effect of both radiation dose and
volume of the heart exposed. Research elucidating the extent to which treatments interact
in causing CVD, and the mechanisms involved, as well as the extent to which treatments
may increase CVD indirectly by increasing cardiovascular risk factors is also important.
Systematic collection of data relating treatment details to late effects is needed, and great
care is needed to obtain valid and generalisable results.
Better knowledge of these cardiac effects will contribute to both primary and secondary
prevention of late complications where exposure to cardiotoxic treatment is unavoidable.
Also surrogate markers would help to identify patients at increased risk of cardiotoxicity.
Evidence-based screening guidelines for CVD following cancer are also needed. Finally, risk
prediction models should be developed to guide primary treatment choice and appropriate
follow up after cancer treatment.
 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction patients with malignancies [1–3]. Unfortunately, they mayImprovement in treatment modalities, including radiotherapy
and systemic therapies, has led to better prognosis foralso induce late effects including an increased risk of cardio-
vascular disease (CVD) in long-term survivors [3,4]. In the gen-
eral population CVDs are major causes of morbidity [5] and
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 1 8 –2 8 19mortality, accounting for 30–50% of all deaths in most devel-
oped countries. Because of this high background rate, even
a minor increase in risk of CVD will have an important impact
on morbidity and mortality.
Heart disease following cancer treatment may be the
result of direct cardiovascular damage caused by the treat-
ment itself or of accelerated atherosclerosis due to cancer
treatment-related cardiovascular risk factors [5]. We will
address both aspects. In this paper we will summarise the
discussion regarding current knowledge and future research
goals from a dedicated workshop which took place at the
1st Cancer Survivorship Summit organised by the European
Organisation for Research and Treatment of Cancer (EORTC)
(January 30, 2014, Brussels, Belgium) and focus on treatment
related heart disease in adult cancer survivors.
2. Current knowledge and gaps in knowledge
2.1. Radiotherapy-related cardiotoxicity
2.1.1. Current knowledge
Radiation-related heart disease includes a variety of cardiac
pathologies, such as coronary artery disease, myocardial dys-
function, pericarditis and valvular heart disease [6–8]. Electri-
cal conduction abnormalities have also been reported but
data are less consistent. Radiation-related pericarditis usually
occurs shortly after exposure. Other radiation-related heart
diseases typically present 10–15 years later [4,7]. Radiation-
related ischaemic heart disease (IHD) is generally observed
at a younger age than IHD in the general population [9–11].
The magnitude of the problem depends on both patient
and treatment characteristics (See Tables 1–3). Evidence for
a dose-dependent relationship for radiation-related heart dis-
ease is accumulating [8,12–14]. Exposure of the heart to even a
low radiation dose may lead to an increased risk. A signifi-
cantly increased risk of death from heart disease (with a lin-
ear dose–response relationship) has been observed among the
Japanese atomic bomb survivors during the 40 years after
exposure to a single dose of <4 Gy [15,16]. Patients treatedTable 1 – Excess risks of cardiac mortality after Hodgkin lymph
Stanford Harvard The Ne
Hoppe et al. [82]
(1997)
Ng et al. [83]
(2002)
Aleman
(2003)
Median age in
years (range)
Not reported 25 (3–50) 25.7 (2–
Interval (years) RR AER RR AER RR
0–5 2 6.4 4.4 6.3 7.6
5–10 3.6 20.1 2.7 5.3 7.0
10–15 3.0 20.5 2.5 7.2 4.5
15–20 5.0 54.2 2.8 13.9 6.8
>20 5.6 70.6 4.5 41.1 8.3
Adapted from ‘‘Long-term complications of lymphoma and its treatmen
Between brackets: year of publication.
BNLI, British National Lymphoma Investigation; CCSS, Childhood Cancer
person years.
* Death from myocardial infarction only.for peptic ulcer with radiotherapy to the stomach had an
increased risk of coronary heart disease which increased with
heart dose (p trend = 0.01)[12]. Increased risks of morbidity
and mortality from CVD have also been observed after treat-
ment for Hodgkin lymphoma [9,17,18]. Reducing the radiation
dose to the heart by shielding a part of the heart (using a sub-
carinal block) reduced the relative risk for cardiac diseases
other than myocardial infarction (MI) [17].
Increased mortality and morbidity from heart disease has
also been reported after radiotherapy for breast cancer (BC),
especially after some of the radiotherapy techniques that
were used in the past [19,20]. Studies on cardiovascular toxic-
ity following radiation for BC frequently compare patients
with left-sided and right-sided BC or compare BC patients
with the general population (taking into account sex, age
and calendar period; see Table 3). Studies comparing patients
who have been irradiated with those who have not have also
been carried out but, unless they are part of a trial in which
patients have been allocated to radiotherapy at random, care
must be taken when interpreting them, as patients selected
for radiotherapy may differ from other patients in terms of
their baseline risks.
In a recent publication 963 women who experienced a
major coronary event after radiotherapy for BC between
1958 and 2001 in Sweden and Denmark were compared with
1205 control women who were also irradiated for BC but did
not have a major coronary event [14]. An increased risk of
major coronary events was observed that started within the
first 5 years after radiotherapy and continued into the third
decade. Themajor coronary event rate increased linearly with
the mean dose to the heart by 7.4% per Gy (95% confidence
interval, 2.9–14.5; P < 0.001), with no apparent threshold.
Classical risk factors for coronary artery disease also influ-
ence the risk of radiation-related CVDs. Higher risks of devel-
oping CVDs following exposure of the heart to radiation have
been observed in patients with classical risk factors for CVDs
[21]. For example in a large study in 10-year survivors of BC,
smoking and radiotherapy together were associated with an
even more than additive effect on risk of MI [22].oma therapy over time.
therlands BNLI* CCSS
et al. [84] Swerdlow et al. [11]
(2007)
Castellino et al. [10]
(2011)
40) Approximately
30 years (all ages)
14 (2–20)
AER RR AER AER
6.1 1.7 4.6 –
10.6 2.3 10.9 5.1
10.7 1.9 8.5 12.3
28.7 4.1 28.9 12.3
53.9 3.1 22.2 25
t’’ Ng et al. [85].
Survival Study; RR, relative risk; AER, absolute excess risk per 10,000
Table 2 – Excess risks of cardiac morbidity after Hodgkin lymphoma therapy.
University of Florida The Netherlands Princess Margaret Hospital Harvard
Hull et al. [86] (2003) Aleman et al. [9] (2007) Myrehaug et al. [26] (2008) Galper et al. [87]
(2011)
RR RR AER RR AER RR AER
CABG 1.63 – – – – 3.2 18
PTCA – – – – – 1.6 18
Valve surgery 8.42 – – – – 9.2 14
Pacemaker – – – – – 1.9 9
MI/angina pectoris – 3.2 61.7 – – – –
CHF – 4.9 25.6 – – – –
Cardiac hospitalisation – – – 1.9 35.6 – –
CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; MI, myocardial infarction; CHF, Congestive heart
failure; RR, relative risk; AER, absolute excess risk.
Adapted from ‘‘Long-term complications of lymphoma and its treatment’’ Ng et al. [85].
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Although our knowledge concerning radiation-related cardio-
toxicity has improved over the last decades there are still
many open questions.
Effects of specific doses to the whole heart and to specific
cardiac substructures have only been assessed in a few
studies [13,14,23]. With the use of more modern radiother-
apy-techniques, such as intensity modulated radiotherapy,
knowledge about the effects of radiotherapy dose and volume
on critical structures of the heart is increasingly important
[24].
Furthermore, data on the separate and combined effects of
modern radiotherapy and cardiotoxic chemo(immuno)ther-
apy on cardiac disease risk have only been addressed in a
small number of studies generally with limited follow-up
[9,11,25,26].
Potential interactions between treatment and lifestyle
factors (e.g. smoking, hypertension, hypercholesterolemia,
premature menopause) need further study especially since
improved knowledge may lead to intervention possibilities.
Early detection of (sub)clinical cardiac damage may be
important but currently there are no specific guidelines for
screening on radiation-related cardiac diseases. At present,
in order to prevent such diseases, screening can be aimed
only at early detection and at treatment of general risk factors
for CVD.
Furthermore, there are indications of large inter-individual
variation of susceptibility to treatment-related toxicity and of
some variation of genetic susceptibility for radiation-related
CVD [27], but further studies are needed.
Since clinical end-points often do not occur until at least
10–15 years after exposure and intervention before they occur
may be useful, adequate imaging screening tools and surro-
gate markers are needed for treatment-related cardiac
diseases.
Better knowledge concerning risk factors and mechanisms
underlying radiation-related CVDs will contribute to primary
and secondary prevention of long-term treatment complica-
tions in cancer survivors where exposure of the heart to radi-
ation is unavoidable.2.2. Cardiotoxicity related to systemic therapy
2.2.1. Current knowledge
The variety of cardiovascular side-effects from systemic can-
cer therapies is diverse and includes the induction of cardiac
dysfunction, myocardial ischaemia, arrhythmias, thrombo-
embolism, arterial and pulmonary hypertension, peripheral
arterial occlusive disease and pleural effusion (Table 4)[28].
Cardiotoxicity following systemic treatment is typically asso-
ciated with loss of myocardial mass, leading to progressive
cardiac remodelling and dysfunction. Patients experiencing
cardiotoxicity develop heart failure (HF) months to years after
the initial cancer therapy and have a severely impaired car-
diovascular prognosis [29]. Anthracyclines are a well known
example of cardiotoxicity; the pathophysiological mechanism
is complex but involves dose-related myocardial cell death
during cancer treatment and possibly an impairment of
reparatory and homoeostatic mechanisms after the exposure
to chemotherapy [30,31]. Signalling inhibitors -such as anti-
HER2 compounds and angiogenesis inhibitors- were also
found to induce cardiac dysfunction. However, in contrast to
anthracyclines these drugs typically lead to cardiac dysfunc-
tion during cancer treatment with a high potential of revers-
ibility [32]. Furthermore, recent data suggest that patients
exposed to trastuzumab have a low risk of progressive cardiac
disease even when followed for years after the initial cancer
treatment [33]. While cancer drug associated, irreversible car-
diotoxicity has recently been termed Type I cardiotoxicity, the
reversible form of cardiac dysfunction was named Type II dys-
function [28]. Other cancer drug related cardiovascular side-
effects with long-term implications for patients include
BCR/ABL tyrosine kinase inhibitor-induced pulmonary hyper-
tension and peripheral arterial occlusive disease [32,34].
These effects typically occur years into treatment with these
compounds and the course of the disease remains unclear.
2.2.2. Gaps in knowledge
Although the cardiotoxic risk of conventional chemothera-
peutics such as anthracyclines has been recognised for more
than 35 years there are still considerable gaps in the
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E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 1 8 –2 8 21understanding of the mechanisms, individual risk factors and
prevention of this side-effect (See Table 5). The cardiotoxicity
problem is increasing since the introduction of anti-cancer
signalling inhibitors that have the potential of causing cardiac
dysfunction itself or increasing cardiotoxicity of conventional
chemotherapeutics [35]. At present, there is no universally
accepted definition of cardiotoxicity and many of the more
recent clinical trials that investigated potentially ‘cardiotoxic’
cancer drugs did not differentiate between Type I cardiotoxic-
ity and Type II cardiac dysfunction. Furthermore, since the
full spectrum of cardiotoxicity frequently does not become
apparent until months or even years after the initial cancer
treatment, long-term follow-up of patients exposed to poten-
tially cardiotoxic cancer drugs is needed and early surrogate
markers predicting long-term cardiovascular prognosis are
wanted. These predictive markers need to be universally
applicable and detect early myocardial loss by, for example,
measuring high-sensitivity cardiac biomarkers [36]. However,
some of the early work with cardiac biomarkers for the pre-
diction of cardiotoxicity has been challenging because the
dynamics of biomarker release after chemotherapy was
unknown and long-term data confirming the predictive value
are missing [37]. It has become clear that the decrease in left
ventricular ejection fraction measured either by echocardiog-
raphy or nuclear scans is not very sensitive in predicting
which patient eventually develops cardiotoxicity [31]. Newer
imaging techniques such as myocardial strain and strain rate
Doppler echocardiography may be more accurate and sensi-
tive to detect early changes of cardiotoxicity [38]. However,
these methods may have technical limitations particularly
in BC patients after left-sided surgery. Numerous preventive
strategies to mitigate cardiotoxicity particularly of anthracy-
clines have been investigated. They included alterations of
the chemical structure, liposomal encapsulation or co-medi-
cations to reduce iron chelation. Although some of these
strategies appeared successful in reducing cardiotoxicity,
questions of impaired efficacy and possible induction of sec-
ond tumours arose [28]. Global guidelines to treat cardiac dys-
function recommend the early use of renin-angiotensin
inhibitors and beta blockers. Although these drugs have been
tested to attenuate anthracycline-associated cardiotoxicity in
single centre studies, convincing evidence from large ran-
domised multicentre trials are still missing [39]. Finally,
although several risk factors for anthracycline-associated car-
diotoxicity have been identified, individual risk assessment in
patients based on genomics and proteomics is still missing.
The recent preclinical discovery that topoisomerase-IIbeta
may mediate anthracycline-associated cardiotoxicity opens
exciting new options: the opportunity to develop topoisomer-
ase-IIalpha specific anthracyclines that are likely less cardio-
toxic and also the potential to predict patient’s individual risk
for anthracycline-associated cardiotoxicity based on their
individual topoisomerase-IIbeta expression [40].
2.3. Metabolic syndrome
2.3.1. Current knowledge
The metabolic syndrome is a clustering of metabolic disor-
ders that is associated with a twofold increased risk of CVD
compared to the general population. Key components of the
Table 5 – Gaps in knowledge concerning cardiotoxicity related to systemic therapy.
Lack of universally accepted definitions of cardiotoxicity and cardiac dysfunction
Differentiation between irreversible and reversible cardiac dysfunction
Long-term follow-up data (10–20 years) needed
Early surrogate markers to predict long-term cardiovascular prognosis
Early pharmacological intervention to mitigate cardiotoxicity
Individualised patient risk assessment
Table 4 – Cardiovascular side-effects of selected systemic cancer therapeutics.
Cardiovascular effect Cancer therapy Long-term effect Mechanism
Cardiotoxicity Type I irreversible Anthracyclines Yes Loss of myocardium
Cyclophosphamide Rare Myocarditis
Cisplatin Rare Unknown
Cardiac dysfunction
Type II reversible
Anti-HER2 Therapeutics Unlikely, except when
combined with anthracyclines
Mitochondrial dysfunction
Anti-VEGF Therapeutics Unlikely Mitochondrial dysfunction
Myocardial ischaemia Pyrimidine analogues Rare Coronary vasospasm
Anti-VEGF therapeutics Rare Arterial thrombosis
Arrhythmia Arsenic trioxide No HERG K+ blockage
Selected TKIs HERG K+ blockage
Thromboembolism Cisplatin Rare Endothelial damage
Anti-VEGF Therapeutics Endothelial damage
Arterial hypertension Anti-VEGF Therapeutics Unknown Multiple mechanisms
Pulmonary hypertension Selected TKIs Unknown Unknown
Peripheral arterial occlusive disease Selected TKIs Unknown Unknown
Pleural effusion Selected TKIs Unknown Unknown
Abbreviations: HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor, HERG
K+, human ether-a-go-go-related gene K+.
22 E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 1 8 –2 8syndrome are decreased insulin sensitivity, hypertension,
overweight and an adverse lipid profile. Unfortunately, differ-
ent classification systems use different criteria to define the
metabolic syndrome, creating heterogeneity in reported prev-
alence between geographical areas and between study popu-
lations [41]. Development of the metabolic syndrome may
contribute to increased CVD risk in prostate cancer patients
using androgen deprivation therapy (ADT), in survivors of tes-
ticular cancer (TC) and of childhood malignancies [42–45].
Following standard cisplatin-based chemotherapy, TC sur-
vivors have an increased prevalence of the metabolic syn-
drome compared with the general male population [46]. The
metabolic syndrome develops early (3–5 years) after treat-
ment and is associated with decreased serum total testoster-
one concentration [47]. Childhood cancer survivors of
haematological malignancies, mainly acute lymphoblastic
leukaemia, and brain tumours have an increased risk of the
metabolic syndrome after cranial, abdominal or total body
irradiation [44,48]. Development of the metabolic syndrome
in these radiotherapy-treated patients is associated with
growth hormone deficiency and hypogonadism. Prostate can-
cer patients may develop an increase in fat mass, a decrease
in lean body mass, an adverse lipid profile, and impaired insu-
lin sensitivity early (within 3–6 months) after start ofandrogen deprivation therapy ADT [49]. These changes differ
from the features of the classically defined metabolic syn-
drome, since ADT induces accumulation of subcutaneous
rather than visceral fat, and an increase rather than a
decrease in high-density lipoprotein cholesterol. Finally, com-
ponents of the metabolic syndrome, including weight gain
and adverse changes in lipid levels, have been reported in
BC survivors [50]. These changes are associated with hor-
monal therapy and with development of early menopause
due to oophorectomy or chemotherapy.
Because of its relatively high prevalence and because of
the effects of the metabolic syndrome in cancer survivors, it
should be addressed in future care plans. Interventional stud-
ies have shown that individuals who make favourable
changes in their lifestyle after cancer diagnosis feel better,
experience less fatigue and may possibly even decrease risk
of cancer recurrence [51].
2.3.2. Gaps in knowledge
Insight into the aetiology of the metabolic syndrome after
cancer treatment might help to identify and treat cancer sur-
vivors with an increased CVD risk.
Development of the metabolic syndrome after cancer ther-
apy is associated with endocrine disorders, mainly growth
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 1 8 –2 8 23hormone deficiency and hypogonadism. However, hormonal
replacement therapy to counteract adverse metabolic
changes can be undesirable from the oncological perspective,
as in prostate cancer patients on ADT. Where it is possible,
intervention trials to establish the size of any effect of hor-
monal replacement therapy and its clinical relevance in can-
cer patients are needed.
Although the metabolic syndrome is associated with an
increased CVD risk, other factors, like smoking, genetic predis-
position, and co-morbidity also contribute to actual CVD risk.
Models incorporating all these factors are needed to better
define patients with high and low CVD risk during follow-up.
Current models estimating ten-year CVD risk, like the Fra-
mingham risk score, are likely to underestimate the CVD risk,
since treatment-related CVD risk certainly continues beyond
ten years in cancer survivors. Therefore, life-time instead of
ten-year risk predictions for CVD are required for cancer sur-
vivor populations. These predictions could identify high risk
groups who would benefit from screening and also aid in
making treatment decisions.
Finally, the prevalence of the metabolic syndrome in survi-
vors treated with both systemic therapy and radiotherapy is
still unknown, but should be assessed during follow-up.
3. Future research
3.1. Learning from the past
There is inevitably uncertainty regarding the long-term
effects of the cancer treatments that are currently in use. In
contrast, the long-term effects of treatments that have been
used in the past can, in principle, be ascertained. However,
the treatment that past patients received is now often consid-
ered to be outdated. For example, radiotherapy for Hodgkin
lymphoma 15–20 years ago consisted of mantle field irradia-
tion up to 40 Gy, a treatment which has little resemblance
to the radiotherapy given today [52]. Likewise, systemic treat-
ment has changed substantially during the past few decades.
Data on long-term complications from former treatments are
still important for long-term survivors treated many years
ago. However, they may lead to an exaggerated fear of treat-
ment modalities that have been available for a long time.
For example modern radiotherapy approaches generally lead
to lower doses to the heart and a dose response relationship
has been shown so, lower risks of CVD are expected [53].
There may also be a tendency to underestimate the risks of
newer treatment modalities for which long term follow-up
information is not available. Nevertheless, the experience of
past patients can be one of the richest sources of information
on the likely long-term consequences of treatments that are
currently in use.
3.2. Randomised trials
One source of information on the long-term experience of
patients, is the information collected during the course of
phase III trials in which patients satisfying certain prespeci-
fied criteria are randomly allocated between two or more dif-
ferent treatment schedules and their subsequent experiencecompared. Data from large randomised trials performed in
the past are particularly useful since treatments were usually
standardised, and direct comparisons between treatments
are possible.
In general, randomised clinical cancer trials are set up
with a time-frame of 5 or 10 years in mind at most. Informa-
tion on CVD occurring during the first 5 or 10 years is infor-
mative [14], but can be of limited use, because many effects
may continue into the second decade after treatment [54]
and possibly even beyond [4,55]. Therefore, additional fol-
low-up is valuable where it can be obtained. The challenge
is to obtain systematic long-term data on patients, since sys-
tematic long-term follow-up of patients is expensive and not
widely practiced today. Long-term survivorship clinics using
dedicated nursing staff and telephone or internet contact
with patients may provide a solution.
However, it is often unnecessary to bring patients into the
clinic to follow them for late effects, and in several countries
useful information can be ascertained at modest cost by
matching the list of patients in the trial against national reg-
isters of vital status, cause of death and hospital diagnoses
[56]. In countries where this is not possible, or where informa-
tion is required on end-points that are not covered by pre-
existing registers, information on late effects can sometimes
be obtained by correspondence with the patients themselves
[13].
As well as the advantages listed above, randomised studies
tend to have some limitations for studying late effects. Indi-
vidual trials often have very low power for the assessment
of late effects (small numbers of patients and/or incomplete
data). This difficulty can be overcome by combining informa-
tion from more than one trial and, preferably, from all the tri-
als carried out in a predefined category, e.g. trials of a
particular drug given for a particular cancer. But even this
may provide only limited power, especially for cancers in
which survival was only moderate at the time the trial was
carried out. Many chemotherapy drugs are, however, used
for several different cancers and for these drugs, information
on late effects from trials carried out in different cancers can
be combined to provide adequate power. To accomplish this,
more cooperation between different disease-orientated
research groups is needed. The Survivorship Taskforce of
the EORTC is promoting this by stimulating collaborative pro-
jects which include data collection and analyses across differ-
ent research groups. In some future research projects detailed
information may be collected on possible risk factors and
outcomes.
A more problematic aspect of the use of randomised trials
for studying late effects is that, as they are not pre-specified
trial end-points, they are often not reported in papers present-
ing trial results unless the findings are in some way remark-
able. Consequently, systematic reviews that rely just on
published information regarding late effects will tend to be
able to present only information from studies with extreme
results, with obvious consequences in terms of bias. This lim-
itation can be overcome by carrying out ameta-analysis based
on individual patient data, although such an approach is
resource intensive as it is usually necessary to contact the ori-
ginal investigators of all the trials in a particular category, and
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ing before it can be analysed.
Another limitation of data arising from randomised trials
is that patients with substantial co-morbidities at the time
of their cancer diagnosis are much less likely to be entered
into randomised trials than patients who are otherwise
healthy. This is likely to be the case even when such patients
are not explicitly excluded in the trial protocol.
A final limitation applies particularly to studies in which
the patients in one arm of the trial have been randomised
to receive potentially cardiotoxic chemotherapy and patients
in the other arm randomised not to receive it. In such trials it
is often the case that the patients in the chemotherapy arm
have their cardiac status more thoroughly assessed –both
during treatment and during follow up- than do patients in
the control arm. This may well introduce considerable bias
into comparisons between the two trial arms for end-points
other than mortality and in such cases meaningful analyses
can only be carried out for cardiac mortality.
3.3. Observational studies
Another approach to obtaining information on the cardiac
side-effects of cancer treatments is to obtain data from
observational studies rather than randomised trials.
Such studies can be informative, especially if they are
population-based as, for example, studies based on large
population-based cancer registries. Care is needed in their
interpretation, however, as patients who are at increased
risk of heart disease at the time when decisions on their
treatment are made, will tend not to be given potentially
cardiotoxic chemotherapy if it can possibly be avoided.
Comparisons of subsequent heart disease rates in patients
with and without such treatment may, therefore, provide
misleading answers [56].
3.4. Achieving relevance for today’s patients
Studies of the long-term cardiac effects of cancer treatments
given in the past may not be immediately relevant to today’s
patients. One reason for this is that medical practice has
changed with time. As mentioned before, modern radiation
approach has significantly reduced normal tissue exposure.
Also in systemic treatment changes have been implemented,
for example, the cardiotoxicity of anthracyclines delivered
today may be lower than previously due to changes in the
way the drug is administered, e.g. by using continuous infu-
sions rather than a bolus or by using a pegylated formulation.
Careful consideration of these issues is therefore needed
when interpreting any studies. A further issue is that baseline
levels of cardiac mortality have decreased substantially over
the last few decades in many countries, and levels of morbid-
ity may have also changed, although such changes are gener-
ally less well documented than changes in mortality. This
may mean that the absolute risk of late cardiac side-effects
in patients treated today may differ from that for past popu-
lations of patients. Proportional increases in the incidence
and mortality arising from the use of particular drugs are,
however, usually reasonably stable across populations with
different baseline rates.The experience of the past can also be used to optimise
future treatments as the data generated from patients treated
in the past may provide dose–response information which
can be used in mathematical models and thereby enable us
to predict and compare long-term complications of present
day treatment, thus guiding the choice of treatment in indi-
vidual patients [57].
For newer treatments such as antibodies, small molecules,
and highly conformal radiotherapy, observation time is still
too short for reliable estimation of long-term complications.
Vigilance and a strict safety-monitoring programme, even
after approval of the drug, are essential.
Furthermore, we need uniform definitions of toxicity in
order to allow proper comparison between studies.
3.5. Regulatory issues
For analysis of long-term complications from specific treat-
ments we often need to be able to obtain data from different
registries on particular, identifiable patients. Hence, ethical
issues must be considered and approvals obtained. In some
countries this may be more difficult than in others since there
is a large variation in regulations concerning these issues.
Informed consent from all relevant patients may be virtu-
ally impossible to obtain retrospectively, since a proportion of
patients will have died or their present address may not be
known. Moreover, there may be ethical dilemmas when con-
tacting patients treated many years ago who now consider
themselves to be healthy. In most countries, permission to
omit informed consent is possible in this situation. Another
approach could be to incorporate upfront permission from
patients entered into clinical trials on future outcomes.
3.6. Early detection of cardiac damage
Information on the possible value of measuring early subclin-
ical damage using biomarkers and/or (functional) imaging fol-
lowing cardiotoxic chemotherapy [58–61] and radiation
exposure of the heart [62] is still scarce.
3.6.1. Imaging
Cardiac imaging techniques such as 2D echocardiography or
MUGA show clinically detectable left-ventricular dysfunction
but earlier subclinical injury cannot be detected with these
imaging modalities. Cardiac magnetic resonance imaging
(MRI) may offer some possibilities in screening since it
enables tissue characterisation and may lead to detection of
diffuse interstitial fibrosis and changes in regional myocardial
function. MRI also has disadvantages such as need for con-
trast, and its high cost and low availability. Newer imaging
techniques, such as contrast and 3D echocardiography are
also under investigation. These imaging modalities are
expensive and should not be unnecessarily repeated. There-
fore, screening guidelines need to be developed and optimal
and cost-effective screening schedules evaluated.
3.6.2. Biomarkers
There are several cardiac biomarkers, such as troponin I (TnI),
troponin T (TnT), B-type natriuretic peptide (BNP), N-terminal
pro-BNP (NT-proBNP) and myeloperoxidase (MPO). There may
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early detection of cardiac toxicity and possibly also during
cancer therapy [63,64]. Circulating cardiac troponin (cTn,
which can be TnI or TnT) is a sensitive and specific biomarker
for detection of myocardial injury. Although most commonly
used to detect myonecrosis in the setting of ischaemia, cTns
are also elevated with other acute and chronic disease pro-
cesses, including HF [65]. An increase in TnI level in patients
undergoing chemotherapy may prove to be a useful means of
detecting cardiotoxicity long before a reduction in left ventric-
ular ejection fraction (LVEF) occurs and could allow for the
selection of high-risk patients who could benefit from preven-
tive treatment, such as treatment with angiotensin-convert-
ing enzyme (ACE) inhibitors and beta-blocking agents. In
patients treated with trastuzumab, an increase in TnI level
could help identifying those patients at risk for cardiotoxicity
and unlikely to recover [66]. So far however, treatment is not
adapted based on troponin levels.
Serum biomarkers may also be useful in helping diagnose
asymptomatic left ventricular dysfunction or HF. Serum bio-
markers such as brain natriuretic peptide (BNP) and N-termi-
nal fragment (NT-proBNP) are most commonly used.
However, there are limitations to BNP or NT-proBNP measure-
ments, since other diseases may also cause abnormal BNP
levels and serum levels also depend on other factors such
as age. In a study analysing eight different biomarkers before
start of treatment and every three months up to 15 months in
patients treated with doxorubicin and trastuzumab, the risk
of cardiotoxicity was especially related to an increase in TnI
and MPO. The combination of both markers offered additive
information about the risk of cardiotoxicity, but independent
validation of these findings is necessary before application to
clinical practice is possible [37]. Another study evaluating 200
patients with anthracycline-induced cardiomyopathy indi-
cated that the percentage of responders to modern HF treat-
ment decreased progressively as the time from the end of
chemotherapy to the start of HF treatment increased [39].
Some biomarkers can also give quantitative information:
the absolute value of these markers shortly after the admin-
istration of chemotherapy may indicate the degree of future
left ventricular dysfunction.
At present there is no clear biomarker-set for CVD risk pre-
diction during or after cancer treatment. Research is on-going
regarding the predictive value and the ideal timing of bio-
marker measurements. Ideally, future research would vali-
date a predictive set of tools to adapt treatment with
respect to toxicity risk. Both biomarkers and imaging need
further exploration in on-going trials. Early imaging, esti-
mated CVD risk and the ability to associate toxicity with
molecular profiling may lead to new recommendations for
monitoring cancer patients during and after chemotherapy.4. Future guidelines
Although the increased risk of cardiac diseases following can-
cer therapy is well recognised, measures for primary and sec-
ondary prevention are still being developed.
Nowadays, cardiac monitoring is done during systemic
treatment by serial measurements of left ventricular ejectionfraction (LVEF). A decrease in LVEF reflects myocardial injury
and the first sign of cardiac failure. Often during chemother-
apy this cardiac dysfunction is reversible, and the LVEF
decrease is only present at the moment of stress. By introduc-
tion of medication or rest, permanent dose reduction or ces-
sation of chemotherapy treatment is not always necessary.
What these moments of severe heart stress induce and the
impact on cardiovascular risk during the rest of life are not
well documented.
Recently, some evidence supports the use of other echo-
cardiographic indices and biomarkers for the earlier detection
of cardiac injury before a decrease in LVEF is noticed [67–71].
New imaging tools and markers are sought for earlier detec-
tion of serious cardiovascular morbidity partly to enable pre-
ventive measures, but also to spare low risk patients from
unnecessary monitoring [72,73].
Currently there are no indications that the management of
cancer treatment related cardiac diseases should differ from
that due to other causes. In patients with (subclinical) HF
treatment generally focuses on correcting underlying physio-
logical abnormalities such as increased afterload and
decreased contractility, and frequently includes treatment
with angiotensin-converting enzyme (ACE) inhibitors and/or
beta-blockers [74]. Several guidelines developed for treating
patients with asymptomatic left ventricular dysfunction or
HF (not specifically after cancer treatment) include e.g. beta-
blockers, ACE-inhibitors and diuretics [75].
At this moment, in Europe formal guidelines exist only fol-
lowing antibody treatment (e.g. echocardiograms every three
months) [76]. More data on incidence and reversibility, but
moreover earlier indicators of cardiac damage, might in the
future enable the necessary level of surveillance to be
individualised.
Although little is formalised on cardiac surveillance fol-
lowing cancer treatment, it is clear that hypertension, short-
ness of breath or chronic fatigue need to be taken very
seriously in cancer survivors. The risk of late cancer treat-
ment related cardiotoxicity is often forgotten or underesti-
mated, especially in women. Guidelines and educational
sessions for general practitioners and other caregivers are
needed to explain late cardiac risks and to better anticipate
on late effects after cancer treatment [77,78].
Lifestyle factors such as smoking, obesity and lack of exer-
cise and familial predisposition are important risk factors in
CVD. Only a few studies have addressed whether factors such
as these may modify the risk of treatment-related CVD [51].
Our knowledge of modifying effects of lifestyle and genetic
predisposition on treatment-associated cardiovascular risk is
only beginning to evolve. International collaborative studies
are needed, including large numbers of survivors for whom
not only treatment data but also detailed high-quality data
onmedical history, lifestyle, environmental, and occupational
factors are available. The sequence of exposure to treatment
and other risk factors deserves investigation, particularly for
designing interventions where the treatments interact with
modifiable risk factors. International pooling of data already
available and data from new studies is essential to obtain suf-
ficient power for interaction analyses allowing discrimination
between additive, multiplicative andmore thanmultiplicative
effects of treatment and other cancer risk factors. Late effects
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lar disease, second malignancies, early menopause, infertility
etc., to obtain more detailed information on host (genetic sen-
sitivity, life style, age etc.) and treatment (dose, type, timing,
interactions etc.) factors. Also the quality of life and psycho-
socio-economic impact should be taken into account, having
possibly a direct (stress) or in-direct (access to care) influence
on morbidity and mortality of various late effects.
Lifestyle interventions, exercise promotion and special
care plans are proposed in cancer survivors. Whether all
patients will benefit from these measures is uncertain. A risk
based strategy is needed and long-term follow-up is essential
[51,79–81].
5. Conclusion
Extensive knowledge has already been gained from the past
concerning cancer treatment related cardiotoxicity, but there
is much more that can be done, although medical practice
continues to evolve and so the resulting data need to be inter-
pretedwith care. Better knowledge is needed of the late effects
ofmodern systemic treatments and of radiotherapy on critical
structures of the heart and of possible interactions between
treatment modalities. This knowledge will contribute to a
longer life expectancy and better quality of life of cancer sur-
vivors, with less treatment-related morbidity from other dis-
eases. Finally, prediction models taking into account the full
spectrum of late effects are needed to guide primary treat-
ment choice and appropriate follow up after cancer treatment.
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